NutriStack
Olmesartan and Potassium, a caution.
Olmesartan blocks the angiotensin II type 1 receptor, suppressing aldosterone and reducing renal potassium excretion. Adding a potassium supplement can produce hyperkalemia, especially in older adults, patients with kidney disease or diabetes, or those also taking NSAIDs, potassium-sparing diuretics, or trimethoprim. Hyperkalemia can be silent until it triggers arrhythmias.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Olmesartan and Potassium
- Pair type
- Caution
- Evidence (highest tier)
- Strong
- Source citations
- 2 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Strong evidence
Caution
What is happening. Olmesartan blocks the angiotensin II type 1 receptor, suppressing aldosterone and reducing renal potassium excretion. Adding a potassium supplement can produce hyperkalemia, especially in older adults, patients with kidney disease or diabetes, or those also taking NSAIDs, potassium-sparing diuretics, or trimethoprim. Hyperkalemia can be silent until it triggers arrhythmias.
Mechanism. AT1 receptor blockade reduces aldosterone secretion and lowers potassium excretion at the cortical collecting duct, so any exogenous potassium load accumulates rather than being eliminated.
Recommendation. Avoid potassium supplements while taking olmesartan unless a deficiency has been confirmed by your prescriber. If both are needed, get potassium checked within 1-2 weeks of starting and after any dose change. Skip potassium-based salt substitutes.
Sources (2)
- Espinel E, Joven J, Gil I, Suñé P, Renedo B, Fort J, Serón D. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Res Notes. 2013;6:306. PMID 23915518
- Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158(1):26-32. PMID 9437375
Stack Score
How this pair moves the number.
Effect on the composite score
If both Olmesartan and Potassium are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.